Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study

Monzr M. Al Malki, Stephanie Bo-Subait, Brent Logan et al. Nov 03, 2025 pp. 936-936 10.1182/blood-2025-936

Abstract Allogeneic hematopoietic cell transplantation (HCT) remains inaccessible to many patients, particularly those of non-European ances...

Cerebral hemodynamic response to chronic transfusion is associated with cerebral vasculopathy in sickle cell anemia

Tara Urner, Rowan Brothers, Jada Oriahi et al. Nov 03, 2025 pp. 531-531 10.1182/blood-2025-531

Abstract Background Diffuse correlation spectroscopy (DCS) is a novel, non-invasive optical technique that measures an i...

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Kim Linton, Franck Morschhauser, Marcel Nijland et al. Nov 03, 2025 pp. 5370-5370 10.1182/blood-2025-5370

Abstract Introduction: Relapsed/refractory follicular lymphoma (R/R FL) is an indolent disease characterized by multiple relapses, with some...

The addition of EBV and C3 complement risk factors formed a better angioimmunoblastic T-cell lymphoma prognostic scoring system

Mengmeng Dong, Yi Zhong, Fang Yu et al. Nov 03, 2025 pp. 7148-7148 10.1182/blood-2025-7148

Abstract Background: Angioimmunoblastic T-cell lymphoma (AITL), a distinct subtype of peripheral T-cell lymphoma (PTCL), exhibits unique cli...

primary CD34+ derived mast cells provide an excellent platform to assess single agent and combination therapies for mastocytosis

Rushil Patel, Yongzhao Huang, Aisha Mergaert et al. Nov 03, 2025 pp. 7278-7278 10.1182/blood-2025-7278

Abstract Mast cells are multi-functional tissue-dwelling cells involved in various pathological conditions such as allergy, asthma, cardiova...

Transfusion burden during the initial induction Phase in Acute Myeloid Leukemia is tightly associated with treatment intensity

Jonathan Canaani, Sarra Yekta, John-William Sidhom et al. Nov 03, 2025 pp. 5172-5172 10.1182/blood-2025-5172

Abstract Introduction The continuously evolving therapeutic landscape of acute myeloid leukemia (AML) in the intensive and non-intensive set...

Regulation of ribosomal RNA synthesis in Acute Myeloid Leukemia

Putzer Hung, Jill Henrich, Charles Antony et al. Nov 03, 2025 pp. 5001-5001 10.1182/blood-2025-5001

Abstract Hematopoiesis generates a complex hierarchy of cells with distinct functions, proliferation rates, and lifespans. A key determinant...

Wildtype NUP98 cooperates with NPM1c to drive oncogenic transcription

Sara Gama, Marcel Müller, Hannah González Dammers et al. Nov 03, 2025 pp. 865-865 10.1182/blood-2025-865

Abstract Nucleophosmin mutations are among the most common aberrations in acute myeloid leukemia (AML). We previously uncovered a novel pivo...

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML

Kazuharu Kamachi, Hiroki Akiyama, Ran Zhao et al. Nov 03, 2025 pp. 5050-5050 10.1182/blood-2025-5050

Abstract Background: Apoptosis resistance drives treatment failure in relapsed/refractory (R/R) acute myeloid leukemia (AML). Targeting non-...

Total marrow and lymphoid irradiation (2000 cGy) together with cyclophosphamide and etoposide prior to allogeneic hematopoietic cell transplantation is an effective regimen for Relapsed/Refractory leukemia, with low non-relapse mortality

Anthony Selwyn Stein, Joycelynne Palmer, Yan Wang et al. Nov 03, 2025 pp. 2441-2441 10.1182/blood-2025-2441

Abstract Background: Total marrow and lymphoid irradiation (TMLI) delivers augmented doses of radiation to the bone marrow (BM) and lymph no...

Bleed-versus-clot paradox under immune-checkpoint inhibition: A decade-long US faers analysis reveals divergent class-specific hemostatic phenotypes

Manzer Ali, Bolivia Fernandes, Kirti Arora et al. Nov 03, 2025 pp. 1313-1313 10.1182/blood-2025-1313

Abstract Background: Immune-checkpoint inhibitors (ICIs) have transformed cancer therapy but can destabilize coagulation, leading to both th...

Immune exhaustion limits CD19 CAR-T efficacy in Richter's transformation

M Bakri Hammami, Constanza Savid-Frontera, Sean Haney et al. Nov 03, 2025 pp. 1791-1791 10.1182/blood-2025-1791

Abstract Background: Despite recent advancements in the treatment of chronic lymphocytic leukemia (CLL), Richter's transformation (RT) into...

Healthcare resource utilization and cost of molecular targeted versus non-targeted therapies in acute myeloid leukemia

Pierantonio Russo, Ramaa Nathan, Daniel Pfeffer et al. Nov 03, 2025 pp. 6207-6207 10.1182/blood-2025-6207

Abstract Background Molecular targeted therapies (MTTs) have provided new treatment options for patients with Acute myeloid leukemia (AML) w...

Velora pioneer, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-002 for prophylaxis in von Willebrand disease: A trial in progress

Priyanka Raheja, Amy Knott, Gillian Lowe et al. Nov 03, 2025 pp. 8230-8230 10.1182/blood-2025-8230

Abstract Background: Von Willebrand Disease (VWD), the most common inherited bleeding disorder, results from quantitative or qualitative def...

Spliceosome mutations in AML: Prevalence, clinical features, and treatment outcomes in a contemporary cohort

Yomna Abu-Farsakh, Emily Zabor, Moath Albliwi et al. Nov 03, 2025 pp. 3396-3396 10.1182/blood-2025-3396

Abstract Background Spliceosomes are intranuclear proteins that splice pre-mRNA into mature mRNA. Somatic mutations in genes encoding spliceo...

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Maria Julia Montoro, Pamela Acha, Franceso Versino et al. Nov 03, 2025 pp. 2070-2070 10.1182/blood-2025-2070

Abstract Background & aim: While SH2B3 gene mutations have been identified in myeloproliferative neoplasms, where they negatively regula...

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

Muhammad Salman Faisal, Nour Nassour, Sean Glenn et al. Nov 03, 2025 pp. 7484-7484 10.1182/blood-2025-7484

Abstract Introduction: The approval of anti-BCMA therapies has significantly expanded the treatment arsenal and has prol...

“I feel like I'm being recognized as being a part of his treatment”: Caregiver perspectives of the serious illness care program for older patients with hematologic malignancies

Jessica Cohen, Conrad Wahl, Marissa Locastro et al. Nov 03, 2025 pp. 6206-6206 10.1182/blood-2025-6206

Abstract Introduction Patients with hematologic malignancies (HMs) often have unpredictable illness trajectories and higher end-of-life heal...

Clinicopathologic features of myeloid neoplasms and pre-neoplasms with isolated ZRSR2 mutations

Alma Oskarsdottir, Rong He, Jennifer Jiang et al. Nov 03, 2025 pp. 7394-7394 10.1182/blood-2025-7394

Abstract Introduction: The ZRSR2 gene, located at Xp22.2, encodes a protein component of the RNA spliceosome. Alterations in ZRSR2 have been...

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

Monzr M. Al Malki, Dongyun Yang, Sally Mokhtari et al. Nov 03, 2025 pp. 2455-2455 10.1182/blood-2025-2455

Abstract Post-transplant cyclophosphamide (PTCy) has emerged as a cornerstone of graft-versus-host disease (GvHD) prophylaxis in reduced int...

Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis

Jianzhen Shen, Xiaofeng Luo, Qian Huang et al. Nov 03, 2025 pp. 7112-7112 10.1182/blood-2025-7112

Abstract Background Zanubrutinib, a next-generation Bruton's tyrosine kinase inhibitor, has shown promise in the management of indolent B-ce...

High rates of hypertension, improved renal outcomes in complement-mediated thrombotic microangiopathy

Charlotte Story, Robert Brodsky, Shruti Chaturvedi Nov 03, 2025 pp. 4884-4884 10.1182/blood-2025-4884

Abstract Background: Our center previously reported a high lifetime prevalence of (HTN), chronic kidney disease (CKD), and major adverse car...

Targeting CSF1R to overcome myeloid cell suppression in CART therapy

Grace DeFranco, Kun Yun, Claudia Manriquez Roman et al. Nov 03, 2025 pp. 5883-5883 10.1182/blood-2025-5883

Abstract Chimeric antigen receptor T (CART) cell therapy has shown unprecedented success in the treatment of hematological malignancies. How...

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Chitra Hosing, Rima M. Saliba, Amin Alousi et al. Nov 03, 2025 pp. 1869-1869 10.1182/blood-2025-1869

Abstract Introduction: T-prolymphocytic leukemia (T-PLL) is a rare subtype of mature T-cell leukemia that is associated with poor outcomes,...

Use of bispecific antibody talquetamab before leukapheresis may lead to out-of-specification ciltacabtagene autoleucel manufacturing: A university of Arizona experience

Jesse Ritter, Danielle Bailey, Numaan Mahmood et al. Nov 03, 2025 pp. 7696-7696 10.1182/blood-2025-7696

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed the management of relapsed or refr...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page